Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

• Main Authors: van Gelder, Michel, Ziagkos, Dimitris, de Wreede, Liesbeth C, van Biezen, Anja, Dreger, Peter, Gramatzki, Martin, Stelljes, Matthias, Smedegaard Andersen, Niels, Schaap, Nicolaas PM, Vitek, Antonin, Beelen, Dietrich, Volin, Liisa, Finke, Jürgen, Passweg, Jakob R, Ganser, Arnold, Machaczka, Maciej J, Delgado, Julio, Krüger, William, Faber, Edgar, Socie, Gerard, Jindra, Pavel, Afanasyev, Boris V, Theobald, Matthias, Chalandon, Yves, Henseler, Anja, Schoenland, Stefan O., Nicolaus, Kroger, Schetelig, Johannes
• Format: Conference Proceeding
• Language: English
• Subjects: Medicin och hälsovetenskap
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V128.22.522.522

Patients with relapsed/refractory chronic lymphocytic leukemia (CLL) have excellent responses with kinase or BCL2 inhibitors, but patients with high risk cytogenetics (del(17p) and/or del(11q)) do not seem to achieve long-term disease control. Allogeneic hematopoietic stem cell transplantation (alloHCT) can result in sustained progression-free survival. As non-relapse mortality (NRM) after alloHCT is partly age-dependent, alloHCT is preferably considered in younger high cytogenetic risk CLL patients, but data of early NRM and longer-term PFS lack for this age group. We focused in this study on younger allo-transplanted CLL patients (